- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02734875
Improving Quality of Care - Managing Atrial Fibrillation Through Care Teams and Health Information Technology (IQ-MATCH)
This stepped wedge randomized intervention will apply machine learning algorithms in an electronic health record system to identify primary care patients with non-valvular atrial fibrillation (AF) who are at high risk of stroke and not on anticoagulation therapy. An Anticoagulant Management Service (AMS) will offer support to primary care providers regarding treatment for relevant patients (either warfarin and novel oral anticoagulants).
This study seeks to:
- increase the proportion of appropriately anticoagulated patients with AF,
- understand the reasons for lack of anticoagulation, and
- document the proportion of patients with AF who are appropriately not anticoagulated (e.g. patient refusal, contraindication).
Studieoversigt
Detaljeret beskrivelse
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with significant mortality and morbidity from stroke, thromboembolism, and related cardiovascular conditions. While the risk of stroke for AF patients as a whole tends to be greater than the general population; within the AF patient population, the risk of stroke is modified by the presence or absence of additional risk factors such as age, comorbid conditions, and prior stroke history.
There is a wealth of evidence for the effectiveness of anticoagulation therapy to prevent stroke and thromboembolism, but while anticoagulants have been demonstrated to be highly effective at preventing stroke and embolic events among AF patients, they are also known to increase the risk of major bleeding events. Anticoagulation with warfarin and other VKA drugs can be complex to manage. These drugs have narrow therapeutic windows and require close monitoring to stay within the target international normalized ratio (INR). They also have many known food and drug interactions.
In the last few years, several novel oral anticoagulants (NOAC) such as dabigatran, rivaroxaban, and apixaban have entered the market. While each of the NOACs demonstrated non-inferiority to warfarin in a large randomized clinical trial prior to FDA approval, experience with NOACs is limited in practice.
Our intervention will combine the ability of health information technology to filter large volumes of data with human capacity to understand subtleties and barriers for complex clinical decision making. Our intervention will facilitate a connection between patients, treating clinicians, and an established Anticoagulant Management Service (AMS) for coordinated care. We will use information from the EHR to direct additional efforts and resources toward reaching potentially unrecognized or undertreated atrial fibrillation patients with the greatest need for preventive anticoagulation therapy and lowest risk of adverse effects. This electronic safety net will assist with efficient allocation of scarce resources beyond usual care. The proposed clinical decision support/care-coordination process will be designed to address many of these identified barriers to appropriate anticoagulation therapy among AF patients. Here we define "appropriate" anticoagulation as a guideline informed shared decision between individual patients and their care team.
This intervention utilizes a stepped wedge design involving 14 primary care clinics affiliated with the Brigham and Women's Hospital. The timing of clinic entry to the intervention arm will be randomized.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Non-valvular atrial fibrillation as identified by machine learning algorithms
- Primary care provider within Brigham and Women's Hospital
- No evidence of a prescription for an anticoagulant in medical record for at least 1 year
Exclusion Criteria:
-
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Intervention
Primary care providers in the intervention arm will receive lists of their patients with AF who are identified as being at high risk of stroke but not currently on anticoagulation therapy.
Along with this list, which includes information on risks and benefits of anticoagulation, primary care providers will receive an offer of assistance from a respected Anticoagulation Management Service within the hospital network to help manage anticoagulation for referred patients.
|
The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
Andre navne:
|
|
Ingen indgriben: Usual Care
Primary care providers will provide usual care.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Anticoagulation therapy
Tidsramme: randomization to 1 month post randomization
|
the proportion of eligible patients who initiate anticoagulation therapy following randomization to intervention or usual care
|
randomization to 1 month post randomization
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2015P000893/BWH
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Atrieflimren
-
W.L.Gore & AssociatesAfsluttetSeptal defekt, atrialForenede Stater
-
Pusan National University HospitalIkke rekrutterer endnuHjerteimplanterbar elektronisk enhed | Atrial High Rate EpisodeKorea, Republikken
-
W.L.Gore & AssociatesAfsluttetSeptal defekt, atrialForenede Stater
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Tilmelding efter invitationKortkoblet idiopatisk ventrikulær fibrillationHolland
-
Henry Ford Health SystemTrukket tilbage
-
Centre Hospitalier Universitaire, AmiensHenri Mondor University HospitalRekrutteringSeptisk chok | Kritisk pleje | Transthorax ekkokardiografi | Speckle Tracking | Reproducerbarhed | Venstre atrial belastning | Højre atrial belastning | Ekkokardiografisk softwareFrankrig
-
Assiut UniversityTrukket tilbageASD2 (Secundum atrial septal defekt)
-
First Affiliated Hospital of Ningbo UniversityAfsluttetEvaluering af radiofrekvensoverført punkteringssystem | Atrial septum punkteringKina
-
Prof. Dr. med. Ingo EitelRekrutteringAtrial hypertensionTyskland
-
Nobles Medical Technologies II IncTilmelding efter invitationForamen Ovale, Patent | Septal defekt, atrial | Septaldefekt, HjerteForenede Stater, Italien
Kliniske forsøg med Intervention
-
Biolux Research Holdings, Inc.AfsluttetOrtodontisk tandbevægelseCanada
-
University of FloridaAfsluttetFølsomhedForenede Stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrutteringBiokemisk tilbagevendende prostatakarcinom | Fase IV prostatakræft AJCC v8 | Stage IVA prostatakræft AJCC v8 | Stadie IVB prostatakræft AJCC v8 | Metastatisk prostataadenokarcinomForenede Stater
-
University of WashingtonNational Cancer Institute (NCI)AfsluttetAvanceret malignt neoplasmaForenede Stater
-
Roswell Park Cancer InstituteAfsluttetFedme | Overvægtig | Anatomisk fase I brystkræft AJCC v8 | Anatomisk fase IA brystkræft AJCC v8 | Anatomisk fase IB brystkræft AJCC v8 | Anatomisk fase II brystkræft AJCC v8 | Anatomisk fase IIA brystkræft AJCC v8 | Anatomisk fase IIB brystkræft AJCC v8 | Anatomisk fase III brystkræft AJCC v8 | Anatomisk fase... og andre forholdForenede Stater
-
Universidad de ExtremaduraDiputación Provincial de BadajozRekrutteringSundhedsuddannelse | Gamification in Health EducationSpanien
-
City of Hope Medical CenterNational Cancer Institute (NCI)AfsluttetBrystkarcinom | Lungekarcinom | Kolorektalt karcinom | Ondartet neoplasma | Blærekarcinom | Malignt kvindeligt reproduktionssystem neoplasmaForenede Stater
-
Mayo ClinicAfsluttet
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAfsluttetOndartet neoplasmaForenede Stater
-
Case Western Reserve UniversityAktiv, ikke rekrutterende